How to buy Innate Pharma S-A stock | $3.91

Innate Pharma S.A is a biotechnology business based in the US. Innate Pharma S-A shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Innate Pharma S-A employs 244 staff and has a trailing 12-month revenue of around 0.00.

Innate Pharma S-A stock price (NASDAQ: IPHA)

Use our graph to track the performance of IPHA stocks over time.

Innate Pharma S-A shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$3.91
52-week range	$3.04 - $6.65
50-day moving average	$3.45
200-day moving average	$4.07
Wall St. target price	$7.19
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Innate Pharma S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Innate Pharma S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Innate Pharma S.A by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Innate Pharma S-A price performance over time

Historical closes compared with the close of $3.91 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	9.83%
3 months (2021-04-30)	-7.78%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Is Innate Pharma S-A under- or over-valued?

Valuing Innate Pharma S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innate Pharma S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Innate Pharma S-A's EBITDA

Innate Pharma S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.3 million.

The EBITDA is a measure of a Innate Pharma S-A's overall financial performance and is widely used to measure a its profitability.

Innate Pharma S-A financials

Revenue TTM	$70.5 million
Gross profit TTM	$11.8 million
Return on assets TTM	-3.27%
Return on equity TTM	-34.27%
Profit margin	-90.82%
Book value	$1.98
Market capitalisation	$262.4 million

TTM: trailing 12 months

Shorting Innate Pharma S-A shares

There are currently 12,792 Innate Pharma S-A shares held short by investors – that's known as Innate Pharma S-A's "short interest". This figure is 98.8% up from 6,435 last month.

There are a few different ways that this level of interest in shorting Innate Pharma S-A shares can be evaluated.

Innate Pharma S-A's "short interest ratio" (SIR)

Innate Pharma S-A's "short interest ratio" (SIR) is the quantity of Innate Pharma S-A shares currently shorted divided by the average quantity of Innate Pharma S-A shares traded daily (recently around 31980). Innate Pharma S-A's SIR currently stands at 0.4. In other words for every 100,000 Innate Pharma S-A shares traded daily on the market, roughly 400 shares are currently held short.

However Innate Pharma S-A's short interest can also be evaluated against the total number of Innate Pharma S-A shares, or, against the total number of tradable Innate Pharma S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innate Pharma S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Innate Pharma S-A shares in existence, roughly 0 shares are currently held short) or 0.0003% of the tradable shares (for every 100,000 tradable Innate Pharma S-A shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Innate Pharma S-A.

Find out more about how you can short Innate Pharma S-A stock.

Innate Pharma S-A share dividends

We're not expecting Innate Pharma S-A to pay a dividend over the next 12 months.

Innate Pharma S-A share price volatility

Over the last 12 months, Innate Pharma S-A's shares have ranged in value from as little as $3.04 up to $6.65. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma S-A's is 0.121. This would suggest that Innate Pharma S-A's shares are less volatile than average (for this exchange).

Innate Pharma S-A overview

Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S. A.

Frequently asked questions

What percentage of Innate Pharma S-A is owned by insiders or institutions?
Currently 1.55% of Innate Pharma S-A shares are held by insiders and 0.378% by institutions. How many people work for Innate Pharma S-A?
Latest data suggests 244 work at Innate Pharma S-A. When does the fiscal year end for Innate Pharma S-A?
Innate Pharma S-A's fiscal year ends in December. Where is Innate Pharma S-A based?
Innate Pharma S-A's address is: 117, Avenue de Luminy, Marseille, France, 13009 What is Innate Pharma S-A's ISIN number?
Innate Pharma S-A's international securities identification number is: US45781K2042 What is Innate Pharma S-A's CUSIP number?
Innate Pharma S-A's Committee on Uniform Securities Identification Procedures number is: 45781K204